JP2018507167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507167A5 JP2018507167A5 JP2017529681A JP2017529681A JP2018507167A5 JP 2018507167 A5 JP2018507167 A5 JP 2018507167A5 JP 2017529681 A JP2017529681 A JP 2017529681A JP 2017529681 A JP2017529681 A JP 2017529681A JP 2018507167 A5 JP2018507167 A5 JP 2018507167A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- pyrazolo
- pyrazin
- pentan
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 249
- 150000001875 compounds Chemical class 0.000 claims description 109
- -1 cyclopropylidene Chemical group 0.000 claims description 72
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 125000005227 alkyl sulfonate group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 claims description 6
- 125000005228 aryl sulfonate group Chemical group 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000951 mycophenolic acid Drugs 0.000 claims description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- UYDZAZNDTNXIDX-OAHLLOKOSA-N (2R)-2-methyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound C[C@@H](CO)CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC UYDZAZNDTNXIDX-OAHLLOKOSA-N 0.000 claims description 2
- BNGZGHJLRLYZLX-XPCCGILXSA-N (2R)-3-[4-[4-[1-(1,1,1-trifluorobutan-2-yl)pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CCC(N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H](O)CO)N=C1)C(F)(F)F BNGZGHJLRLYZLX-XPCCGILXSA-N 0.000 claims description 2
- IHZCYGIKKXIIOQ-QAPCUYQASA-N (2R)-3-[4-[4-[1-[(3S)-2,2-difluoropentan-3-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound FC(C)([C@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2)F IHZCYGIKKXIIOQ-QAPCUYQASA-N 0.000 claims description 2
- ITIFSOSGXOSPND-DUSLRRAJSA-N (2R)-3-[4-[4-[1-[1-(3,3-difluorocyclobutyl)propyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound FC1(CC(C1)C(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2)F ITIFSOSGXOSPND-DUSLRRAJSA-N 0.000 claims description 2
- UYDZAZNDTNXIDX-HNNXBMFYSA-N (2S)-2-methyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound C[C@H](CO)CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC UYDZAZNDTNXIDX-HNNXBMFYSA-N 0.000 claims description 2
- BIQLFOVHGXFGRI-GOSISDBHSA-N (3R)-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,3-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H](CCO)O)N=CC=2 BIQLFOVHGXFGRI-GOSISDBHSA-N 0.000 claims description 2
- BIQLFOVHGXFGRI-SFHVURJKSA-N (3S)-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,3-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H](O)CCO)N=C1 BIQLFOVHGXFGRI-SFHVURJKSA-N 0.000 claims description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- KITCYDCXSZDXLF-UHFFFAOYSA-N 1-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]piperazin-2-one Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CCN2CCNCC2=O)N=C1 KITCYDCXSZDXLF-UHFFFAOYSA-N 0.000 claims description 2
- OANLOJFGMDFXLE-UHFFFAOYSA-N 2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C(CO)CO OANLOJFGMDFXLE-UHFFFAOYSA-N 0.000 claims description 2
- NGAAOEYVYQJXJR-UHFFFAOYSA-N 2-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]butan-1-ol Chemical compound CCC(CO)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C)N=C1 NGAAOEYVYQJXJR-UHFFFAOYSA-N 0.000 claims description 2
- LNWZSEFHRUUIPB-UHFFFAOYSA-N 2-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]butanoic acid Chemical compound CCC(N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C)N=C1)C(O)=O LNWZSEFHRUUIPB-UHFFFAOYSA-N 0.000 claims description 2
- VHBISBSNGUVGTR-UHFFFAOYSA-N 2-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclopentan-1-ol Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C1C(CCC1)O VHBISBSNGUVGTR-UHFFFAOYSA-N 0.000 claims description 2
- NAGSKGCXMWXMFR-UHFFFAOYSA-N 2-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]propan-1-ol Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CO)C NAGSKGCXMWXMFR-UHFFFAOYSA-N 0.000 claims description 2
- NJJAFIJJCFMWSU-UHFFFAOYSA-N 3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCCO)N=CC=2 NJJAFIJJCFMWSU-UHFFFAOYSA-N 0.000 claims description 2
- PBBVBJNUBYULHP-UHFFFAOYSA-N 3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]pentan-1-ol Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CCO)CC PBBVBJNUBYULHP-UHFFFAOYSA-N 0.000 claims description 2
- OUPNAKMUTDMSBJ-UHFFFAOYSA-N 4-(1-cycloheptylpyrazol-4-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1CCCCCC1 OUPNAKMUTDMSBJ-UHFFFAOYSA-N 0.000 claims description 2
- XENRQMHKPAIYOY-UHFFFAOYSA-N 4-[1-(1-ethoxyethyl)pyrazol-4-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CCOC(C)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C)N=C1 XENRQMHKPAIYOY-UHFFFAOYSA-N 0.000 claims description 2
- KRTPHJWJOAAJKP-UHFFFAOYSA-N 4-[1-(1-methylcyclopentyl)pyrazol-4-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1(C)CCCC1 KRTPHJWJOAAJKP-UHFFFAOYSA-N 0.000 claims description 2
- CIJCUJJBEHAVNW-UHFFFAOYSA-N 4-[1-(2-methylcycloheptyl)pyrazol-4-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C1C(CCCCC1)C CIJCUJJBEHAVNW-UHFFFAOYSA-N 0.000 claims description 2
- IRPRWEJXPIFLLK-UHFFFAOYSA-N 4-[1-(3-methylpentan-3-yl)pyrazol-4-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)(CC)C IRPRWEJXPIFLLK-UHFFFAOYSA-N 0.000 claims description 2
- 108020004491 Antisense DNA Proteins 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- OLPLCLUQAIDUNC-UHFFFAOYSA-N [2-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclopentyl]methanol Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1CCCC1CO OLPLCLUQAIDUNC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 230000002280 anti-androgenic effect Effects 0.000 claims description 2
- 230000003388 anti-hormonal effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000000051 antiandrogen Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000003816 antisense DNA Substances 0.000 claims description 2
- 125000005362 aryl sulfone group Chemical group 0.000 claims description 2
- 229940092117 atgam Drugs 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000008512 biological response Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229960002706 gusperimus Drugs 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229960000681 leflunomide Drugs 0.000 claims description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 239000003558 transferase inhibitor Substances 0.000 claims description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 42
- 239000004146 Propane-1,2-diol Substances 0.000 claims 21
- 229960004063 propylene glycol Drugs 0.000 claims 21
- 235000013772 propylene glycol Nutrition 0.000 claims 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 14
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 3
- RRUMNCYHIPZCJS-AWEZNQCLSA-N (2S)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)[C@@H](C)CO RRUMNCYHIPZCJS-AWEZNQCLSA-N 0.000 claims 2
- KQQKJEIPZFYFJH-UHFFFAOYSA-N 1-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]ethanone Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C1CN(C1)C(C)=O)N=CC=2 KQQKJEIPZFYFJH-UHFFFAOYSA-N 0.000 claims 2
- QXNBQQFEJLEJRY-UHFFFAOYSA-N 3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CC(C1)C(N)=O QXNBQQFEJLEJRY-UHFFFAOYSA-N 0.000 claims 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- NZWKRMFCKXOQMF-UHFFFAOYSA-N N-(2-hydroxyethyl)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CC(C1)C(=O)NCCO NZWKRMFCKXOQMF-UHFFFAOYSA-N 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- PFOVYMSLQMATJJ-UHFFFAOYSA-N (1-hydroxycyclopropyl)-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]methanone Chemical compound OC1(CC1)C(=O)N1CC(C1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC PFOVYMSLQMATJJ-UHFFFAOYSA-N 0.000 claims 1
- DVXZLEHKUCHABK-TZIWHRDSSA-N (1R,2R)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclopentan-1-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]1[C@@H](CCC1)O)N=CC=2 DVXZLEHKUCHABK-TZIWHRDSSA-N 0.000 claims 1
- DVXZLEHKUCHABK-PZJWPPBQSA-N (1R,2S)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclopentan-1-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]1[C@@H](CCC1)O)N=CC=2 DVXZLEHKUCHABK-PZJWPPBQSA-N 0.000 claims 1
- DVXZLEHKUCHABK-QWAKEFERSA-N (1S)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclopentan-1-ol Chemical compound CCC(CC)N1C=C(C=N1)C2=NC(=CN3C2=CC=N3)C4=CN(N=C4)C5CCC[C@@H]5O DVXZLEHKUCHABK-QWAKEFERSA-N 0.000 claims 1
- DVXZLEHKUCHABK-FPOVZHCZSA-N (1S,2S)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]cyclopentan-1-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]1[C@H](CCC1)O)N=CC=2 DVXZLEHKUCHABK-FPOVZHCZSA-N 0.000 claims 1
- ZQULBRPQLXZJAR-OAQYLSRUSA-N (2R)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]-3-pyrrolidin-1-ylpropan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H](CN1CCCC1)O)N=CC=2 ZQULBRPQLXZJAR-OAQYLSRUSA-N 0.000 claims 1
- AMTYSNROYXSBLL-GOSISDBHSA-N (2R)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H](CC)O)N=CC=2 AMTYSNROYXSBLL-GOSISDBHSA-N 0.000 claims 1
- KDFZIACXAYYZLE-CQSZACIVSA-N (2R)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H](C)O)N=CC=2 KDFZIACXAYYZLE-CQSZACIVSA-N 0.000 claims 1
- ISWBZDSAQHLONO-GOSISDBHSA-N (2R)-1-methoxy-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H](O)COC)N=C1 ISWBZDSAQHLONO-GOSISDBHSA-N 0.000 claims 1
- SMROVSFEANQWIQ-LJQANCHMSA-N (2R)-2-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]morpholine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H]1CNCCO1)N=CC=2 SMROVSFEANQWIQ-LJQANCHMSA-N 0.000 claims 1
- IPKHOCAMRZYLHH-MRXNPFEDSA-N (2R)-2-amino-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound N[C@@H](CO)CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC IPKHOCAMRZYLHH-MRXNPFEDSA-N 0.000 claims 1
- OIAGAWSCJMASIN-GOSISDBHSA-N (2R)-2-methoxy-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-amine Chemical compound CO[C@H](CN)CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC OIAGAWSCJMASIN-GOSISDBHSA-N 0.000 claims 1
- ACJCSGITKCJZNM-OAQYLSRUSA-N (2R)-2-methyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@](C)(O)CO)N=C1 ACJCSGITKCJZNM-OAQYLSRUSA-N 0.000 claims 1
- JTBCMVGGBDUBFT-QGZVFWFLSA-N (2R)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 JTBCMVGGBDUBFT-QGZVFWFLSA-N 0.000 claims 1
- LCEUZFIUMGLKJG-PSDZMVHGSA-N (2R)-3-[4-[4-[1-(1-phenylpropyl)pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C1(=CC=CC=C1)C(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 LCEUZFIUMGLKJG-PSDZMVHGSA-N 0.000 claims 1
- JTYBFCFEYKYPMC-GOSISDBHSA-N (2R)-3-[4-[4-[1-(dicyclopropylmethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound OC[C@H](O)CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C(C1CC1)C1CC1 JTYBFCFEYKYPMC-GOSISDBHSA-N 0.000 claims 1
- RMZLLPSCCIOKBY-UYAOXDASSA-N (2R)-3-[4-[4-[1-[(1R)-1-cyclobutylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C1(CCC1)[C@@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 RMZLLPSCCIOKBY-UYAOXDASSA-N 0.000 claims 1
- HGUMRBROBXBLAK-IEBWSBKVSA-N (2R)-3-[4-[4-[1-[(1R)-1-cyclopropylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC[C@H](C1CC1)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H](O)CO)N=C1 HGUMRBROBXBLAK-IEBWSBKVSA-N 0.000 claims 1
- WDHJXPHWQBPKAW-XFQXTVEOSA-N (2R)-3-[4-[4-[1-[(1R,2R)-2-methylcyclohexyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C[C@H]1[C@@H](CCCC1)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 WDHJXPHWQBPKAW-XFQXTVEOSA-N 0.000 claims 1
- KCFVSZJMFSMFCF-QKYXUNIQSA-N (2R)-3-[4-[4-[1-[(1R,2S)-2-ethylcyclopentyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C(C)[C@@H]1[C@@H](CCC1)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 KCFVSZJMFSMFCF-QKYXUNIQSA-N 0.000 claims 1
- VELXQPPVCPGIEB-POZUXBRTSA-N (2R)-3-[4-[4-[1-[(1R,2S)-2-methylcyclopentyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C[C@@H]1[C@@H](CCC1)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 VELXQPPVCPGIEB-POZUXBRTSA-N 0.000 claims 1
- HGUMRBROBXBLAK-MJGOQNOKSA-N (2R)-3-[4-[4-[1-[(1S)-1-cyclopropylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C1(CC1)[C@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 HGUMRBROBXBLAK-MJGOQNOKSA-N 0.000 claims 1
- KCFVSZJMFSMFCF-ZTNFWEORSA-N (2R)-3-[4-[4-[1-[(1S,2R)-2-ethylcyclopentyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC[C@@H]1CCC[C@@H]1N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H](O)CO)N=C1 KCFVSZJMFSMFCF-ZTNFWEORSA-N 0.000 claims 1
- HGTQRXMBFVRIFR-QBIMZIAESA-N (2R)-3-[4-[4-[1-[(1S,2R)-2-methylcyclobutyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C[C@@H]1CC[C@@H]1n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@@H](O)CO)c1 HGTQRXMBFVRIFR-QBIMZIAESA-N 0.000 claims 1
- VELXQPPVCPGIEB-BJZITVGISA-N (2R)-3-[4-[4-[1-[(1S,2R)-2-methylcyclopentyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C[C@H]1[C@H](CCC1)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 VELXQPPVCPGIEB-BJZITVGISA-N 0.000 claims 1
- FISCYOFARSRLSI-RTBURBONSA-N (2R)-3-[4-[4-[1-[(2R)-1-cyclopropylbutan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C1(CC1)C[C@@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2 FISCYOFARSRLSI-RTBURBONSA-N 0.000 claims 1
- XOLGTWQACRYHDY-CRAIPNDOSA-N (2R)-3-[4-[4-[1-[(2R)-4-methylpentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC(C[C@@H](C)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2)C XOLGTWQACRYHDY-CRAIPNDOSA-N 0.000 claims 1
- PVXMSOSQLLPNEY-CZUORRHYSA-N (2R)-3-[4-[4-[1-[(2R)-butan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC[C@@H](C)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@@H](O)CO)c1 PVXMSOSQLLPNEY-CZUORRHYSA-N 0.000 claims 1
- XOLGTWQACRYHDY-MAUKXSAKSA-N (2R)-3-[4-[4-[1-[(2S)-4-methylpentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC(C[C@H](C)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CO)O)N=CC=2)C XOLGTWQACRYHDY-MAUKXSAKSA-N 0.000 claims 1
- FMWDSXYJPDRLET-GOSISDBHSA-N (2R)-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC[C@H](CO)O)N=CC=2 FMWDSXYJPDRLET-GOSISDBHSA-N 0.000 claims 1
- RLBJLTMGMDYGHH-JLTOFOAXSA-N (2R,3R)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-2,3-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H]([C@@H](C)O)O)N=CC=2 RLBJLTMGMDYGHH-JLTOFOAXSA-N 0.000 claims 1
- YONOAVIZYZCVJG-TZIWHRDSSA-N (2R,3R)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]oxolan-3-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)[C@@H]1OCC[C@H]1O YONOAVIZYZCVJG-TZIWHRDSSA-N 0.000 claims 1
- JPDLPQUDPUKPTI-HUUCEWRRSA-N (2R,3R)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]([C@@H](C)O)C)N=CC=2 JPDLPQUDPUKPTI-HUUCEWRRSA-N 0.000 claims 1
- WDHNKTSCLXJOSV-VLIAUNLRSA-N (2R,3R)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]([C@H](CO)O)C)N=CC=2 WDHNKTSCLXJOSV-VLIAUNLRSA-N 0.000 claims 1
- JPDLPQUDPUKPTI-LSDHHAIUSA-N (2R,3S)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]([C@@H](C)O)C)N=CC=2 JPDLPQUDPUKPTI-LSDHHAIUSA-N 0.000 claims 1
- WDHNKTSCLXJOSV-XOBRGWDASA-N (2R,3S)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]([C@H](CO)O)C)N=CC=2 WDHNKTSCLXJOSV-XOBRGWDASA-N 0.000 claims 1
- ZQULBRPQLXZJAR-NRFANRHFSA-N (2S)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]-3-pyrrolidin-1-ylpropan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CN1CCCC1)O)N=CC=2 ZQULBRPQLXZJAR-NRFANRHFSA-N 0.000 claims 1
- AMTYSNROYXSBLL-SFHVURJKSA-N (2S)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H](CC)O)N=CC=2 AMTYSNROYXSBLL-SFHVURJKSA-N 0.000 claims 1
- LZEQHKULKROZGJ-IFXJQAMLSA-N (2S)-1-[4-[4-[1-[(1R)-1-cyclopropylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound CC[C@H](C1CC1)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@H](C)O)N=C1 LZEQHKULKROZGJ-IFXJQAMLSA-N 0.000 claims 1
- ISWBZDSAQHLONO-SFHVURJKSA-N (2S)-1-methoxy-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound COC[C@H](CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O ISWBZDSAQHLONO-SFHVURJKSA-N 0.000 claims 1
- SMROVSFEANQWIQ-IBGZPJMESA-N (2S)-2-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]morpholine Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@@H]2CNCCO2)N=C1 SMROVSFEANQWIQ-IBGZPJMESA-N 0.000 claims 1
- OIAGAWSCJMASIN-SFHVURJKSA-N (2S)-2-methoxy-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-amine Chemical compound CO[C@@H](CN)CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC OIAGAWSCJMASIN-SFHVURJKSA-N 0.000 claims 1
- ACJCSGITKCJZNM-NRFANRHFSA-N (2S)-2-methyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound C[C@@](CO)(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O ACJCSGITKCJZNM-NRFANRHFSA-N 0.000 claims 1
- JTBCMVGGBDUBFT-KRWDZBQOSA-N (2S)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@H](O)CO)N=C1 JTBCMVGGBDUBFT-KRWDZBQOSA-N 0.000 claims 1
- LQWPZLUGOSYIHL-FQEVSTJZSA-N (2S)-3-methyl-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-2,3-diol Chemical compound CC([C@H](CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O)(C)O LQWPZLUGOSYIHL-FQEVSTJZSA-N 0.000 claims 1
- FMWDSXYJPDRLET-SFHVURJKSA-N (2S)-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC[C@@H](CO)O)N=CC=2 FMWDSXYJPDRLET-SFHVURJKSA-N 0.000 claims 1
- JPDLPQUDPUKPTI-CABCVRRESA-N (2S,3R)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]([C@H](C)O)C)N=CC=2 JPDLPQUDPUKPTI-CABCVRRESA-N 0.000 claims 1
- WDHNKTSCLXJOSV-JLTOFOAXSA-N (2S,3R)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]([C@@H](CO)O)C)N=CC=2 WDHNKTSCLXJOSV-JLTOFOAXSA-N 0.000 claims 1
- RLBJLTMGMDYGHH-XOBRGWDASA-N (2S,3S)-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-2,3-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H]([C@H](C)O)O)N=CC=2 RLBJLTMGMDYGHH-XOBRGWDASA-N 0.000 claims 1
- YONOAVIZYZCVJG-FPOVZHCZSA-N (2S,3S)-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]oxolan-3-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)[C@H]1OCC[C@@H]1O YONOAVIZYZCVJG-FPOVZHCZSA-N 0.000 claims 1
- JPDLPQUDPUKPTI-GJZGRUSLSA-N (2S,3S)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]([C@H](C)O)C)N=CC=2 JPDLPQUDPUKPTI-GJZGRUSLSA-N 0.000 claims 1
- WDHNKTSCLXJOSV-VBKZILBWSA-N (2S,3S)-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,2-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)[C@@H](C)[C@H](O)CO WDHNKTSCLXJOSV-VBKZILBWSA-N 0.000 claims 1
- XWEGZOWJKZVIPT-HXUWFJFHSA-N (3R)-1-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]pyrrolidin-3-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1C[C@@H](CC1)O)N=CC=2 XWEGZOWJKZVIPT-HXUWFJFHSA-N 0.000 claims 1
- PRDYSVHWSCSUOP-VGAJERRHSA-N (3R)-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]piperidin-3-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CCNC[C@H]1O PRDYSVHWSCSUOP-VGAJERRHSA-N 0.000 claims 1
- XWEGZOWJKZVIPT-FQEVSTJZSA-N (3S)-1-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]pyrrolidin-3-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1C[C@H](CC1)O)N=CC=2 XWEGZOWJKZVIPT-FQEVSTJZSA-N 0.000 claims 1
- RYBLPYLDSOXGLN-SFHVURJKSA-N (3S)-3-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]morpholine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H]1NCCOC1)N=CC=2 RYBLPYLDSOXGLN-SFHVURJKSA-N 0.000 claims 1
- OLRNUXJNQGODGR-FQEVSTJZSA-N (3S)-3-amino-2-methyl-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(C[C@H](N)C(C)(C)O)N=C1 OLRNUXJNQGODGR-FQEVSTJZSA-N 0.000 claims 1
- GKVKDWDOTDUVOW-QGZVFWFLSA-N (5R)-5-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]pyrrolidin-2-one Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@H]1CCC(N1)=O)N=CC=2 GKVKDWDOTDUVOW-QGZVFWFLSA-N 0.000 claims 1
- GKVKDWDOTDUVOW-KRWDZBQOSA-N (5S)-5-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]pyrrolidin-2-one Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C[C@@H]1CCC(N1)=O)N=CC=2 GKVKDWDOTDUVOW-KRWDZBQOSA-N 0.000 claims 1
- QBLXLZIGBYSMLZ-UHFFFAOYSA-N 1-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]piperidin-4-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1CCC(CC1)O)N=CC=2 QBLXLZIGBYSMLZ-UHFFFAOYSA-N 0.000 claims 1
- PYPRSGPYVFWABX-UHFFFAOYSA-N 1-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]-2-pyrrolidin-1-ylethanone Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C1CN(C1)C(CN1CCCC1)=O)N=CC=2 PYPRSGPYVFWABX-UHFFFAOYSA-N 0.000 claims 1
- IBNMAQFIGSSRFF-UHFFFAOYSA-N 1-[4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]piperidin-1-yl]ethanone Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CCN(CC1)C(C)=O IBNMAQFIGSSRFF-UHFFFAOYSA-N 0.000 claims 1
- ODXJPWQJGRKWJV-UHFFFAOYSA-N 1-[4-hydroxy-4-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]piperidin-1-yl]ethanone Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC2(O)CCN(CC2)C(C)=O)N=C1 ODXJPWQJGRKWJV-UHFFFAOYSA-N 0.000 claims 1
- SDNGLJCJUQMLCR-UHFFFAOYSA-N 1-amino-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC(O)CN)N=C1 SDNGLJCJUQMLCR-UHFFFAOYSA-N 0.000 claims 1
- JFWKUYOSILBESK-UHFFFAOYSA-N 1-morpholin-4-yl-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethanone Chemical compound O1CCN(CC1)C(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)=O JFWKUYOSILBESK-UHFFFAOYSA-N 0.000 claims 1
- QVZXJVILZBKCPS-UHFFFAOYSA-N 2,2-dimethyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC(C)(C)CO)N=C1 QVZXJVILZBKCPS-UHFFFAOYSA-N 0.000 claims 1
- ZYSRHJWNCKTYPB-UHFFFAOYSA-N 2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethanesulfonamide Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCS(=O)(=O)N)N=CC=2 ZYSRHJWNCKTYPB-UHFFFAOYSA-N 0.000 claims 1
- AGRPWNNPBIPBLB-UHFFFAOYSA-N 2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethanol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CCO)N=C1 AGRPWNNPBIPBLB-UHFFFAOYSA-N 0.000 claims 1
- RULCSAQHHGBMIE-LJQANCHMSA-N 2-[4-[4-[1-[(1R)-1-cyclopropylpropyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound C1(CC1)[C@@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C(CO)CO)N=CC=2 RULCSAQHHGBMIE-LJQANCHMSA-N 0.000 claims 1
- BGXDMZAQLSQTKH-FOIQADDNSA-N 2-[4-[4-[1-[(1R,2R)-2-methylcyclohexyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound C[C@@H]1CCCC[C@H]1N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C(CO)CO BGXDMZAQLSQTKH-FOIQADDNSA-N 0.000 claims 1
- HKYGFMCMDMUWNA-OAHLLOKOSA-N 2-[4-[4-[1-[(2R)-4-methylpentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound CC(C[C@@H](C)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C(CO)CO)N=CC=2)C HKYGFMCMDMUWNA-OAHLLOKOSA-N 0.000 claims 1
- PFHQZHDUKYAXNC-CQSZACIVSA-N 2-[4-[4-[1-[(2R)-pentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound C[C@H](CCC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C(CO)CO)N=CC=2 PFHQZHDUKYAXNC-CQSZACIVSA-N 0.000 claims 1
- HKYGFMCMDMUWNA-HNNXBMFYSA-N 2-[4-[4-[1-[(2S)-4-methylpentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound CC(C[C@H](C)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C(CO)CO)N=CC=2)C HKYGFMCMDMUWNA-HNNXBMFYSA-N 0.000 claims 1
- PFHQZHDUKYAXNC-AWEZNQCLSA-N 2-[4-[4-[1-[(2S)-pentan-2-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound CCC[C@H](C)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C(CO)CO PFHQZHDUKYAXNC-AWEZNQCLSA-N 0.000 claims 1
- YUPQNKRHPPLOHL-HNNXBMFYSA-N 2-[4-[4-[1-[(3S)-1,1,1-trifluoropentan-3-yl]pyrazol-4-yl]pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,3-diol Chemical compound FC(C[C@H](CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C(CO)CO)N=CC=2)(F)F YUPQNKRHPPLOHL-HNNXBMFYSA-N 0.000 claims 1
- NYNMTZMWURTOON-UHFFFAOYSA-N 2-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]propane-1,3-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC(CO)CO)N=CC=2 NYNMTZMWURTOON-UHFFFAOYSA-N 0.000 claims 1
- YCELUTLXURKQPL-UHFFFAOYSA-N 2-amino-1-[4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]piperidin-1-yl]ethanone Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CCN(CC1)C(=O)CN YCELUTLXURKQPL-UHFFFAOYSA-N 0.000 claims 1
- WCUCAMQCKSJIOD-UHFFFAOYSA-N 2-hydroxy-1-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]ethanone Chemical compound OCC(=O)N1CC(C1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC WCUCAMQCKSJIOD-UHFFFAOYSA-N 0.000 claims 1
- MVXIGKROFJNEBN-UHFFFAOYSA-N 2-methoxy-1-[4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]piperidin-1-yl]ethanone Chemical compound COCC(=O)N1CCC(CC1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC MVXIGKROFJNEBN-UHFFFAOYSA-N 0.000 claims 1
- GJZRWHRQSBNKRS-UHFFFAOYSA-N 2-methyl-1-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]propan-1-one Chemical compound CC(C(=O)N1CC(C1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C GJZRWHRQSBNKRS-UHFFFAOYSA-N 0.000 claims 1
- KQHQNBIOGBNAOH-UHFFFAOYSA-N 2-methyl-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-2-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC(C)(C)O)N=C1 KQHQNBIOGBNAOH-UHFFFAOYSA-N 0.000 claims 1
- LIRSAFKJCZZQQI-UHFFFAOYSA-N 2-methyl-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C(C)(C)CO LIRSAFKJCZZQQI-UHFFFAOYSA-N 0.000 claims 1
- ACJCSGITKCJZNM-UHFFFAOYSA-N 2-methyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CC(CO)(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O ACJCSGITKCJZNM-UHFFFAOYSA-N 0.000 claims 1
- OOTOILRGUDIKTF-UHFFFAOYSA-N 3,3-dimethyl-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CC(C(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O)(C)C OOTOILRGUDIKTF-UHFFFAOYSA-N 0.000 claims 1
- JTBCMVGGBDUBFT-UHFFFAOYSA-N 3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propane-1,2-diol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC(CO)O)N=CC=2 JTBCMVGGBDUBFT-UHFFFAOYSA-N 0.000 claims 1
- BAZXVQQXNBSIOH-UHFFFAOYSA-N 3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]thietane 1,1-dioxide Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C1CS(C1)(=O)=O)N=CC=2 BAZXVQQXNBSIOH-UHFFFAOYSA-N 0.000 claims 1
- DQXFMJHFGXBZOS-UHFFFAOYSA-N 3-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]cyclobutan-1-ol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC2CC(O)C2)N=C1 DQXFMJHFGXBZOS-UHFFFAOYSA-N 0.000 claims 1
- SOHKNIOEGMHCFT-UHFFFAOYSA-N 3-methyl-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound CC(C(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O)C SOHKNIOEGMHCFT-UHFFFAOYSA-N 0.000 claims 1
- SGQLCLSFJLVFRY-UHFFFAOYSA-N 4,4,4-trifluoro-1-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butan-2-ol Chemical compound FC(CC(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)O)(F)F SGQLCLSFJLVFRY-UHFFFAOYSA-N 0.000 claims 1
- IOFIUNRBSNSVEI-UHFFFAOYSA-N 4-(1-pentan-3-ylpyrazol-4-yl)-6-(1-piperidin-4-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C1CCNCC1)N=CC=2 IOFIUNRBSNSVEI-UHFFFAOYSA-N 0.000 claims 1
- ZMGDLXDDHGOYDT-UHFFFAOYSA-N 4-(1-pentan-3-ylpyrazol-4-yl)-6-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyrazine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1CCCC1)N=CC=2 ZMGDLXDDHGOYDT-UHFFFAOYSA-N 0.000 claims 1
- AJAWHQDUZDCYMQ-UHFFFAOYSA-N 4-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]morpholine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1CCOCC1)N=CC=2 AJAWHQDUZDCYMQ-UHFFFAOYSA-N 0.000 claims 1
- AQXLZXBTAYHUHU-UHFFFAOYSA-N 4-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]piperazin-2-one Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1CC(NCC1)=O)N=CC=2 AQXLZXBTAYHUHU-UHFFFAOYSA-N 0.000 claims 1
- BIQLFOVHGXFGRI-UHFFFAOYSA-N 4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]butane-1,3-diol Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC(O)CCO)N=C1 BIQLFOVHGXFGRI-UHFFFAOYSA-N 0.000 claims 1
- KPNPTVBBJSTLHR-UHFFFAOYSA-N 4-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]oxan-4-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC1(CCOCC1)O)N=CC=2 KPNPTVBBJSTLHR-UHFFFAOYSA-N 0.000 claims 1
- ZUXWPTUABRHWBA-UHFFFAOYSA-N 4-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]piperidin-4-ol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC1(CCNCC1)O)N=CC=2 ZUXWPTUABRHWBA-UHFFFAOYSA-N 0.000 claims 1
- RJJDBVLQFUOSJC-UHFFFAOYSA-N 4-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]thiane 1,1-dioxide Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC1CCS(CC1)(=O)=O)N=CC=2 RJJDBVLQFUOSJC-UHFFFAOYSA-N 0.000 claims 1
- XBNDSSWRAWNRLV-UHFFFAOYSA-N 5-[[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]methyl]-1,3-oxazolidin-2-one Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(CC2CNC(=O)O2)N=C1 XBNDSSWRAWNRLV-UHFFFAOYSA-N 0.000 claims 1
- VFCFWIPNIDSBSK-UHFFFAOYSA-N 6-(1-piperidin-4-ylpyrazol-4-yl)-4-(1-propan-2-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound C(C)(C)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)C1CCNCC1)N=CC=2 VFCFWIPNIDSBSK-UHFFFAOYSA-N 0.000 claims 1
- KBKFIKWCFFXFIH-UHFFFAOYSA-N 6-[1-(1-methylsulfonylazetidin-3-yl)pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CCC(CC)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CN(N=C1)C1CN(C1)S(C)(=O)=O KBKFIKWCFFXFIH-UHFFFAOYSA-N 0.000 claims 1
- RBNSBPUEWYMQRJ-UHFFFAOYSA-N 6-[1-(1-methylsulfonylpiperidin-4-yl)pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CS(=O)(=O)N1CCC(CC1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC RBNSBPUEWYMQRJ-UHFFFAOYSA-N 0.000 claims 1
- YQBQXLRNAYEBCY-UHFFFAOYSA-N 6-[1-(2-methylsulfonylethyl)pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CS(=O)(=O)CCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC YQBQXLRNAYEBCY-UHFFFAOYSA-N 0.000 claims 1
- DWXUDRWPYWVKRB-UHFFFAOYSA-N 6-[1-(3-methylsulfonylpropyl)pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CS(=O)(=O)CCCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC DWXUDRWPYWVKRB-UHFFFAOYSA-N 0.000 claims 1
- AOFUXVYOOMKRGG-UHFFFAOYSA-N 6-[1-(oxan-4-ylmethyl)pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CC1CCOCC1)N=CC=2 AOFUXVYOOMKRGG-UHFFFAOYSA-N 0.000 claims 1
- ZFVDBFPIDVFUKU-UHFFFAOYSA-N 6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine Chemical compound FC1CN(C1)CCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC ZFVDBFPIDVFUKU-UHFFFAOYSA-N 0.000 claims 1
- IEVXFOVMPBXOPB-RHDGDCLCSA-N CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]1C[C@H](C1)CO)N=CC=2 Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@@H]1C[C@H](C1)CO)N=CC=2 IEVXFOVMPBXOPB-RHDGDCLCSA-N 0.000 claims 1
- IEVXFOVMPBXOPB-GLRZTSSQSA-N CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]1C[C@H](C1)CO)N=CC=2 Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)[C@H]1C[C@H](C1)CO)N=CC=2 IEVXFOVMPBXOPB-GLRZTSSQSA-N 0.000 claims 1
- XKXIKQUEJCAHFW-UHFFFAOYSA-N N,N-dimethyl-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]acetamide Chemical compound CN(C(CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)=O)C XKXIKQUEJCAHFW-UHFFFAOYSA-N 0.000 claims 1
- WKIYBLMNYFYECG-UHFFFAOYSA-N N,N-dimethyl-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethanamine Chemical compound CN(CCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C WKIYBLMNYFYECG-UHFFFAOYSA-N 0.000 claims 1
- YJDGQJNGBWFSJB-UHFFFAOYSA-N N,N-dimethyl-2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethanesulfonamide Chemical compound CN(S(=O)(=O)CCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C YJDGQJNGBWFSJB-UHFFFAOYSA-N 0.000 claims 1
- LLYUJAVJZYINHJ-UHFFFAOYSA-N N,N-dimethyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidine-1-carboxamide Chemical compound CN(C(=O)N1CC(C1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C LLYUJAVJZYINHJ-UHFFFAOYSA-N 0.000 claims 1
- GWFPRBLVHXNVTL-UHFFFAOYSA-N N,N-dimethyl-3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]propan-1-amine Chemical compound CN(CCCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C GWFPRBLVHXNVTL-UHFFFAOYSA-N 0.000 claims 1
- LDDOGZGJPXCIRH-UHFFFAOYSA-N N,N-dimethyl-4-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]piperidine-1-carboxamide Chemical compound CN(C(=O)N1CCC(CC1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC)C LDDOGZGJPXCIRH-UHFFFAOYSA-N 0.000 claims 1
- VXWDADMWHBDHHT-UHFFFAOYSA-N N-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]cyclopropanamine Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCNC1CC1)N=CC=2 VXWDADMWHBDHHT-UHFFFAOYSA-N 0.000 claims 1
- QXJOOPZPQAEKRC-UHFFFAOYSA-N N-methyl-N-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]methanesulfonamide Chemical compound CN(S(=O)(=O)C)CCN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC QXJOOPZPQAEKRC-UHFFFAOYSA-N 0.000 claims 1
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- KNAGBHSVICAWIT-UHFFFAOYSA-N [1-[2-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]ethyl]piperidin-4-yl]methanol Chemical compound CCC(CC)N1N=CC(=C1)C=1C=2N(C=C(N=1)C=1C=NN(C=1)CCN1CCC(CC1)CO)N=CC=2 KNAGBHSVICAWIT-UHFFFAOYSA-N 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 230000002927 anti-mitotic effect Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- IYVOSOGNUVUYQM-UHFFFAOYSA-N cyclopropyl-[3-[4-[4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl]pyrazol-1-yl]azetidin-1-yl]methanone Chemical compound C1(CC1)C(=O)N1CC(C1)N1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C(CC)CC IYVOSOGNUVUYQM-UHFFFAOYSA-N 0.000 claims 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- CMGKRWOBNPTZBW-UHFFFAOYSA-N pyrazolo[1,5-a]pyrazine Chemical compound C1=NC=CN2N=CC=C21 CMGKRWOBNPTZBW-UHFFFAOYSA-N 0.000 claims 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims 1
- ZWNHDUPLKJBMEF-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4(CO)O)nc3)c[n]3nccc23)c1 ZWNHDUPLKJBMEF-UHFFFAOYSA-N 0.000 description 3
- 0 *C(*)(*)[n]1ncc(B(O*)I)c1 Chemical compound *C(*)(*)[n]1ncc(B(O*)I)c1 0.000 description 2
- IEVXFOVMPBXOPB-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C4CC(CO)C4)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C4CC(CO)C4)nc3)c[n]3nccc23)c1 IEVXFOVMPBXOPB-UHFFFAOYSA-N 0.000 description 2
- GQMPILIYOVYDCB-CXGRPWHSSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@@]4(C)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@@]4(C)O)nc3)c[n]3nccc23)c1 GQMPILIYOVYDCB-CXGRPWHSSA-N 0.000 description 2
- YPBHFJWUPLVJAN-IUODEOHRSA-N C[C@H](CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound C[C@H](CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 YPBHFJWUPLVJAN-IUODEOHRSA-N 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- XOLGTWQACRYHDY-UHFFFAOYSA-O CC(C)CC(C)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 Chemical compound CC(C)CC(C)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 XOLGTWQACRYHDY-UHFFFAOYSA-O 0.000 description 1
- XOLGTWQACRYHDY-KPMSDPLLSA-N CC(C)CC(C)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(C)CC(C)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 XOLGTWQACRYHDY-KPMSDPLLSA-N 0.000 description 1
- OFCMDVUPHREYDA-UHFFFAOYSA-O CC(C)CC(C)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 Chemical compound CC(C)CC(C)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 OFCMDVUPHREYDA-UHFFFAOYSA-O 0.000 description 1
- SSCCJQJLIGWQAF-MBIQTGHCSA-N CC(C)[C@H](C)[n]1ncc(-c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(C)[C@H](C)[n]1ncc(-c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)c1 SSCCJQJLIGWQAF-MBIQTGHCSA-N 0.000 description 1
- GMFUJOMNTOHGCD-UHFFFAOYSA-O CC(CC(F)(F)F)[N+2]1N=CC(c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)=C1 Chemical compound CC(CC(F)(F)F)[N+2]1N=CC(c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)=C1 GMFUJOMNTOHGCD-UHFFFAOYSA-O 0.000 description 1
- YPBHFJWUPLVJAN-WPZCJLIBSA-N CC(CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC(CC(F)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 YPBHFJWUPLVJAN-WPZCJLIBSA-N 0.000 description 1
- IHZCYGIKKXIIOQ-UHFFFAOYSA-O CCC(C(C)(F)F)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 Chemical compound CCC(C(C)(F)F)[NH+]1N=CC(c2nc(-c3c[n](CC(CO)O)nc3)c[n]3nccc23)=C1 IHZCYGIKKXIIOQ-UHFFFAOYSA-O 0.000 description 1
- IHZCYGIKKXIIOQ-NNJIEVJOSA-N CCC(C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C(C)(F)F)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 IHZCYGIKKXIIOQ-NNJIEVJOSA-N 0.000 description 1
- UVCKTYRTYZYKSN-PHDNBGSHSA-O CCC(C(F)(F)F)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NCC(CO)=O)c[n]3nccc23)c1 Chemical compound CCC(C(F)(F)F)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NCC(CO)=O)c[n]3nccc23)c1 UVCKTYRTYZYKSN-PHDNBGSHSA-O 0.000 description 1
- NICFJHSFKDJWCZ-UHFFFAOYSA-N CCC(C1)(CN1S(C(F)(F)F)(=O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 Chemical compound CCC(C1)(CN1S(C(F)(F)F)(=O)=O)[n]1ncc(-c2nc(-c3c[n](C)nc3)c[n]3nccc23)c1 NICFJHSFKDJWCZ-UHFFFAOYSA-N 0.000 description 1
- RMZLLPSCCIOKBY-QSVWIEALSA-N CCC(C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 RMZLLPSCCIOKBY-QSVWIEALSA-N 0.000 description 1
- JGPOTKRWWPQJSK-UHFFFAOYSA-O CCC(CC(F)(F)F)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 Chemical compound CCC(CC(F)(F)F)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CC(CO)O)c[n]3nccc23)c1 JGPOTKRWWPQJSK-UHFFFAOYSA-O 0.000 description 1
- CGQVSZWMAXJEFB-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[nH]nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[nH]nc3)c[n]3nccc23)c1 CGQVSZWMAXJEFB-UHFFFAOYSA-N 0.000 description 1
- HJUVFZGONSIZFY-UHFFFAOYSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n](C(C4)CC4O)nc3)c[n]3nccc23)c1 HJUVFZGONSIZFY-UHFFFAOYSA-N 0.000 description 1
- ZWNHDUPLKJBMEF-LBZQVFOQSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@]4(CO)O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](C4)C[C@]4(CO)O)nc3)c[n]3nccc23)c1 ZWNHDUPLKJBMEF-LBZQVFOQSA-N 0.000 description 1
- QUUKMKOJWSAHRW-FIWHBWSRSA-N CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](COC4)C4O)nc3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(-c3c[n]([C@H](COC4)C4O)nc3)c[n]3nccc23)c1 QUUKMKOJWSAHRW-FIWHBWSRSA-N 0.000 description 1
- PRKDQOTWBOKRQZ-UHFFFAOYSA-O CCC(CC)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CCN3CCC(CO)CC3)c[n]3nccc23)c1 Chemical compound CCC(CC)[n]1ncc(-c2nc(C(C=N)=C[NH2+]CCN3CCC(CO)CC3)c[n]3nccc23)c1 PRKDQOTWBOKRQZ-UHFFFAOYSA-O 0.000 description 1
- PSDYYKIZXFXLFY-DNAVFNFUSA-O CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@@H](CO)O)c[n]3nccc23)c1 Chemical compound CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@@H](CO)O)c[n]3nccc23)c1 PSDYYKIZXFXLFY-DNAVFNFUSA-O 0.000 description 1
- PSDYYKIZXFXLFY-UVDRRPMQSA-O CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@H](CO)O)c[n]3nccc23)c1 Chemical compound CCC[C@@H](C)[n]1ncc(-c2nc(/C(/C=[NH2+])=C/NC[C@H](CO)O)c[n]3nccc23)c1 PSDYYKIZXFXLFY-UVDRRPMQSA-O 0.000 description 1
- QCMKOFSIVHBTCV-JERBSLHSSA-N CC[C@@H](C(C)(F)F)N(/C=C(\C)/c1nc(-c2c[n](C[C@H](CO)O)nc2)c[n]2nccc12)N=C Chemical compound CC[C@@H](C(C)(F)F)N(/C=C(\C)/c1nc(-c2c[n](C[C@H](CO)O)nc2)c[n]2nccc12)N=C QCMKOFSIVHBTCV-JERBSLHSSA-N 0.000 description 1
- RMZLLPSCCIOKBY-QUCCMNQESA-N CC[C@@H](C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 Chemical compound CC[C@@H](C1CCC1)[n]1ncc(-c2nc(-c3c[n](C[C@H](CO)O)nc3)c[n]3nccc23)c1 RMZLLPSCCIOKBY-QUCCMNQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088068P | 2014-12-05 | 2014-12-05 | |
| US62/088,068 | 2014-12-05 | ||
| PCT/US2015/064062 WO2016090285A1 (en) | 2014-12-05 | 2015-12-04 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019223760A Division JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507167A JP2018507167A (ja) | 2018-03-15 |
| JP2018507167A5 true JP2018507167A5 (enExample) | 2019-01-24 |
| JP6641373B2 JP6641373B2 (ja) | 2020-02-05 |
Family
ID=55069089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529681A Expired - Fee Related JP6641373B2 (ja) | 2014-12-05 | 2015-12-04 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
| JP2019223760A Pending JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019223760A Pending JP2020055859A (ja) | 2014-12-05 | 2019-12-11 | ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10189845B2 (enExample) |
| EP (2) | EP3878451A1 (enExample) |
| JP (2) | JP6641373B2 (enExample) |
| KR (1) | KR20170090476A (enExample) |
| CN (1) | CN107278203B (enExample) |
| AU (1) | AU2015357585B2 (enExample) |
| BR (1) | BR112017011798A2 (enExample) |
| CA (1) | CA2969709A1 (enExample) |
| CL (1) | CL2017001422A1 (enExample) |
| CO (1) | CO2017006674A2 (enExample) |
| CR (1) | CR20170309A (enExample) |
| DK (1) | DK3227297T3 (enExample) |
| ES (1) | ES2865483T3 (enExample) |
| HR (1) | HRP20210501T1 (enExample) |
| HU (1) | HUE054371T2 (enExample) |
| IL (1) | IL252656A0 (enExample) |
| MX (1) | MX386316B (enExample) |
| MY (1) | MY191016A (enExample) |
| PH (1) | PH12017501032A1 (enExample) |
| PL (1) | PL3227297T3 (enExample) |
| PT (1) | PT3227297T (enExample) |
| RS (1) | RS61693B1 (enExample) |
| RU (2) | RU2742938C2 (enExample) |
| SG (1) | SG11201704542SA (enExample) |
| SI (1) | SI3227297T1 (enExample) |
| TW (1) | TWI725004B (enExample) |
| UA (1) | UA120065C2 (enExample) |
| WO (1) | WO2016090285A1 (enExample) |
| ZA (1) | ZA201704494B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61693B1 (sr) | 2014-12-05 | 2021-05-31 | Array Biopharma Inc | 4,6-supstituisani-pirazolo[1,5-a]pirazini kao inhibitori janus kinaze |
| EP3712153B1 (en) | 2016-02-24 | 2021-12-01 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| UA126231C2 (uk) | 2016-06-16 | 2022-09-07 | Деналі Терапьютікс Інк. | Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CN110267960B (zh) * | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| US20200157081A1 (en) * | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3668858A1 (en) | 2017-08-14 | 2020-06-24 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
| ES2981909T3 (es) * | 2019-04-12 | 2024-10-11 | Primegene Beijing Co Ltd | Compuestos derivados de pirazolopirazina, composición farmacéutica y utilización de los mismos |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CN113150012B (zh) * | 2020-01-22 | 2023-03-24 | 浙江海正药业股份有限公司 | 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途 |
| EP4125900A1 (en) | 2020-04-04 | 2023-02-08 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP7748560B2 (ja) * | 2021-11-12 | 2025-10-02 | シーエムエス リサーチ アンド ディベロップメント ピーティーイー リミテッド | ピラゾロ縮合環化合物及びその使用 |
| AU2024274086A1 (en) * | 2023-05-12 | 2026-01-08 | Cms Research & Development Pte. Ltd. | Pyrazolopyrazine compound and method for preparing crystal form thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69924500T2 (de) | 1998-08-21 | 2006-02-09 | Parker Hughes Institute, St. Paul | Chinazolinderivate |
| DE102007032349A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| HUE025177T2 (en) | 2009-12-23 | 2016-02-29 | Takeda Pharmaceuticals Co | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| WO2011089400A1 (en) * | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| US20110241987A1 (en) * | 2010-04-01 | 2011-10-06 | Smart Technologies Ulc | Interactive input system and information input method therefor |
| CA2796388A1 (en) | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| SG11201401342VA (en) * | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| UA112795C2 (uk) * | 2012-03-28 | 2016-10-25 | Мерк Патент Гмбх | Біциклічні піразинонові похідні |
| RS61693B1 (sr) | 2014-12-05 | 2021-05-31 | Array Biopharma Inc | 4,6-supstituisani-pirazolo[1,5-a]pirazini kao inhibitori janus kinaze |
-
2015
- 2015-12-04 RS RS20210415A patent/RS61693B1/sr unknown
- 2015-12-04 PL PL15819933T patent/PL3227297T3/pl unknown
- 2015-12-04 BR BR112017011798A patent/BR112017011798A2/pt not_active IP Right Cessation
- 2015-12-04 RU RU2017123387A patent/RU2742938C2/ru active
- 2015-12-04 JP JP2017529681A patent/JP6641373B2/ja not_active Expired - Fee Related
- 2015-12-04 HU HUE15819933A patent/HUE054371T2/hu unknown
- 2015-12-04 TW TW104140878A patent/TWI725004B/zh not_active IP Right Cessation
- 2015-12-04 RU RU2021102805A patent/RU2021102805A/ru unknown
- 2015-12-04 CR CR20170309A patent/CR20170309A/es unknown
- 2015-12-04 HR HRP20210501TT patent/HRP20210501T1/hr unknown
- 2015-12-04 DK DK15819933.1T patent/DK3227297T3/da active
- 2015-12-04 CA CA2969709A patent/CA2969709A1/en not_active Abandoned
- 2015-12-04 EP EP21152373.3A patent/EP3878451A1/en not_active Withdrawn
- 2015-12-04 US US15/532,937 patent/US10189845B2/en active Active
- 2015-12-04 MX MX2017007284A patent/MX386316B/es unknown
- 2015-12-04 UA UAA201707008A patent/UA120065C2/uk unknown
- 2015-12-04 ES ES15819933T patent/ES2865483T3/es active Active
- 2015-12-04 CN CN201580066136.5A patent/CN107278203B/zh not_active Expired - Fee Related
- 2015-12-04 PT PT158199331T patent/PT3227297T/pt unknown
- 2015-12-04 AU AU2015357585A patent/AU2015357585B2/en not_active Ceased
- 2015-12-04 MY MYPI2017702034A patent/MY191016A/en unknown
- 2015-12-04 SI SI201531544T patent/SI3227297T1/sl unknown
- 2015-12-04 WO PCT/US2015/064062 patent/WO2016090285A1/en not_active Ceased
- 2015-12-04 EP EP15819933.1A patent/EP3227297B1/en active Active
- 2015-12-04 SG SG11201704542SA patent/SG11201704542SA/en unknown
- 2015-12-04 KR KR1020177018122A patent/KR20170090476A/ko not_active Withdrawn
-
2017
- 2017-06-02 PH PH12017501032A patent/PH12017501032A1/en unknown
- 2017-06-04 IL IL252656A patent/IL252656A0/en active IP Right Grant
- 2017-06-05 CL CL2017001422A patent/CL2017001422A1/es unknown
- 2017-06-30 CO CONC2017/0006674A patent/CO2017006674A2/es unknown
- 2017-07-03 ZA ZA2017/04494A patent/ZA201704494B/en unknown
-
2018
- 2018-12-06 US US16/212,493 patent/US10730880B2/en active Active
-
2019
- 2019-12-11 JP JP2019223760A patent/JP2020055859A/ja active Pending
-
2020
- 2020-06-02 US US16/890,663 patent/US11028093B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507167A5 (enExample) | ||
| US11028093B2 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| ES2956087T3 (es) | Compuestos inhibidores de RIP1 y métodos para preparar y usar los mismos | |
| US9593115B2 (en) | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | |
| JP5788507B2 (ja) | 置換３−フェニル−１，２，４−オキサジアゾール化合物 | |
| US11926616B2 (en) | Aminopyrazine diol compounds as PI3K-γ inhibitors | |
| IL267215B (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
| BG107236A (bg) | ПИРОЛО[2,3-d] ПИРИМИДИНОВИ СЪЕДИНЕНИЯ КАТО ИМУНОДЕПРЕСИВНИ СРЕДСТВА | |
| TW202140491A (zh) | 吡咯并[1,2-b]嗒𠯤衍生物 | |
| NZ518884A (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| CA2904797A1 (en) | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer | |
| US10150762B2 (en) | Trifluoromethyl alcohols as modulators of RORγt | |
| US20130096149A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| CA2918284A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| TWI727392B (zh) | 噻二唑irak4抑制劑 | |
| US20210198251A1 (en) | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | |
| JP2017508736A (ja) | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 | |
| JP2024542881A (ja) | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 | |
| TW202302113A (zh) | 用於治療肉瘤之化合物 | |
| JP2019529453A (ja) | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 | |
| JP7209415B2 (ja) | ピラゾロピリミジン化合物、医薬組成物、及びその使用 | |
| US20250059175A1 (en) | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | |
| HK1238236B (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| CA3016364A1 (en) | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |